Gastrointestinal tolerability and quality of life in antiretroviral-naïve HIV-1-infected patients: data from the CASTLE study

References

• Burgoyne , R.W. and Tan , D.H. 2008 . Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): A balancing act . Journal of Antimicrobial Chemotherapy , 61 ( 3 ) : 469 – 473 .
   PubMed Web of Science ®Google Scholar
• Crum , N.F. , Riffenburgh , R.H. , Wegner , S. , Agan , B.K. , Tasker , S.A. Spooner , K.M. 2006 . Comparisons of causes of death and mortality rates among HIV-infected persons: Analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras . Journal of Acquired Immune Deficiency Syndrome , 41 ( 2 ) : 194 – 200 .
   PubMed Web of Science ®Google Scholar
• Cunningham , W.E. , Shapiro , M.F. , Hays , R.D. , Dixon , W.J. , Visscher , B.R. George , W.L. 1998 . Constitutional symptoms and health-related quality of life in patients with symptomatic HIV disease . American Journal of Medicine , 104 ( 2 ) : 129 – 136 .
   PubMed Web of Science ®Google Scholar
• Drossman , D.A. , Patrick , D.L. , Whitehead , W.E. , Toner , B.B. , Diamant , N.E. Hu , Y. 2000 . Further validation of the IBS-QOL: A disease-specific quality-of-life questionnaire . American Journal of Gastroenterology , 95 ( 4 ) : 999 – 1007 .
   PubMed Web of Science ®Google Scholar
• Eron , J. , Jr. , Yeni , P. , Gathe , J. , Jr. , Estrada , V. , DeJesus , E. , Staszewski , S. , et al. 2006 . The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: A randomised non-inferiority trial . Lancet , 368 9534 , 476 482 .
   PubMed Web of Science ®Google Scholar
• Gathe , J. , da Silva , B. Loutfy , M. 2008 , February 3–6 . Study M05-730 primary efficacy results at week 48: Phase 3, randomized, open-label study of lopinavir/ritonavir tablets once daily vs. twice daily, co-administered with tenofovir and emtricitabine in ARV-naive HIV-1-infected subjects . Presented at 15th Conference on retrovirus and opportunistic infections (CROI), Boston, MA.
   Google Scholar
• Gazzard , B. , Bernard , A.J. , Boffito , M. , Churchill , D. , Edwards , S. Fisher , N. 2006 . British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006) . HIV Medicine , 7 ( 8 ) : 487 – 503 .
   PubMed Web of Science ®Google Scholar
• Lodwick , R.K. , Smith , C.J. , Youle , M. , Lampe , F.C. , Tyrer , M. Bhagani , S. 2008 . Stability of antiretroviral regimens in patients with viral suppression . AIDS , 22 ( 9 ) : 1039 – 1046 .
   PubMed Web of Science ®Google Scholar
• Lubeck , D.P. , Bennett , C.L. , Mazonson , P.D. , Fifer , S.K. and Fries , J.F. 1993 . Quality of life and health service use among HIV-infected patients with chronic diarrhea . Journal of Acquired Immune Deficiency Syndrome , 6 ( 5 ) : 478 – 484 .
   PubMed Web of Science ®Google Scholar
• Mocroft , A. , Ledergerber , B. , Katlama , C. , Kirk , O. , Reiss , P. d'Arminio , M.A. 2003 . Decline in the AIDS and death rates in the EuroSIDA study: An observational study . Lancet , 362 ( 9377 ) : 22 – 29 .
   PubMed Web of Science ®Google Scholar
• Molina , J.M. , Andrade-Villanueva , J. , Echevarria , J. , Chetchotisakd , P. , Corral , J. , David , N. , et al. 2008a , October 25–26 . Atazanavir/ritonavir vs lopinavir/ritonavir in antiretroviral naive HIV-1 infected patients: CASTLE 96 week efficacy and safety . Presented at 48th Annual ICAAC/IDSA Annual Meeting, Washington, DC .
   Google Scholar
• Molina , J.M. , Andrade-Villanueva , J. , Echevarria , J. , Chetchotisakd , P. , Corral , J. David , N. 2008b . Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study . Lancet , 372 ( 9639 ) : 646 – 655 .
   PubMed Web of Science ®Google Scholar
• Munakata , J. , Benner , J.S. , Becker , S. , Dezii , C.M. , Hazard , E.H. and Tierce , J.C. 2006 . Clinical and economic outcomes of nonadherence to highly active antiretroviral therapy in patients with human immunodeficiency virus . Medical Care , 44 ( 10 ) : 893 – 899 .
   PubMed Web of Science ®Google Scholar
• O'Brien , M.E. , Clark , R.A. , Besch , C.L. , Myers , L. and Kissinger , P. 2003 . Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort . Journal of Acquired Immune Deficiency Syndrome , 34 ( 4 ) : 407 – 414 .
   PubMed Web of Science ®Google Scholar
• Ortiz , R. , DeJesus , E. , Khanlou , H. , Voronin , E. , van Lunzen , J. Andrade-Villanueva , J. 2008 . Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48 . AIDS , 22 ( 12 ) : 1389 – 1397 .
   PubMed Web of Science ®Google Scholar
• Park-Wyllie , L.Y. , Strike , C.S. , Antoniou , T. and Bayoumi , A.M. 2007 . Adverse quality of life consequences of antiretroviral medications . AIDS Care , 19 ( 2 ) : 252 – 257 .
   PubMed Web of Science ®Google Scholar
• Rachlis , A. , Gill , J. , Baril , J.G. , LeBlanc , R.P. , Trottier , B. MacLeod , J. 2005 . Effectiveness of step-wise intervention plan for managing nelfinavir-associated diarrhea: A pilot study . HIV Clinical Trials , 6 ( 4 ) : 203 – 212 .
   PubMed Web of Science ®Google Scholar
• Schiller , D.S. 2004 . Identification, management, and prevention of adverse effects associated with highly active antiretroviral therapy . American Journal of Health System Pharmacy , 61 ( 23 ) : 2507 – 2522 .
   PubMed Web of Science ®Google Scholar
• Sherman , D.S. and Fish , D.N. 2000 . Management of protease inhibitor-associated diarrhea . Clinical Infectious Diseases , 30 ( 6 ) : 908 – 914 .
   PubMed Web of Science ®Google Scholar
• Snijders , F. , de Boer , J.B. , Steenbergen , B. , Schouten , M. , Danner , S.A. and van Dam , F.S. 1998 . Impact of diarrhoea and faecal incontinence on the daily life of HIV-infected patients . AIDS Care , 10 ( 5 ) : 629 – 637 .
   PubMed Web of Science ®Google Scholar
• Torti , C. and Frank , I. 2008 . A king in the CASTLE? Optimum initial HIV protease inhibitor . Lancet , 372 ( 9639 ) : 604 – 606 .
   PubMed Web of Science ®Google Scholar
• Uy , J. , Yang , R. , Thiry , A. , Absalon , J. , Farajallah , A. , Maa , J. , et al. 2008 , November 9–13 . Efficacy and safety by baseline HIV RNA and CD4 count in treatment-naïve patients treated with atazanavir/RTV and lopinavir/RTV in the CASTLE study . Presented at Ninth International Congress on Drug Therapy in HIV Infection, Glasgow, UK .
   Google Scholar
• Vo , T.T. , Ledergerber , B. , Keiser , O. , Hirschel , B. , Furrer , H. Battegay , M. 2008 . Durability and outcome of initial antiretroviral treatments received during 2000–2005 by patients in the Swiss HIV Cohort Study . Journal of Infectious Diseases , 197 ( 12 ) : 1685 – 1694 .
   PubMed Web of Science ®Google Scholar
• Watson , A. , Samore , M.H. and Wanke , C.A. 1996 . Diarrhea and quality of life in ambulatory HIV-infected patients . Digestive Disease and Science , 41 ( 9 ) : 1794 – 1800 .
   PubMed Web of Science ®Google Scholar